| Chronic Kidney Diseases
Inpefa vs Renvela
Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.Deep comparison between: Inpefa vs Renvela with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRenvela has a higher rate of injection site reactions vs Inpefa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Renvela but not Inpefa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inpefa
Renvela
At A Glance
Oral
Daily
SGLT1/SGLT2 inhibitor
Oral
Three times daily with meals
Phosphate binder
Indications
- Heart failure
- Diabetes Mellitus, Non-Insulin-Dependent
- Chronic Kidney Diseases
- Chronic Kidney Diseases
Dosing
Heart failure, Diabetes Mellitus, Non-Insulin-Dependent, Chronic Kidney Diseases 200 mg orally once daily, not more than one hour before the first meal; titrate after at least 2 weeks to 400 mg once daily as tolerated; down-titrate to 200 mg as necessary.
Chronic Kidney Diseases (Adults) Starting dose 0.8-1.6 g orally three times daily with meals based on serum phosphorus level; titrate by 0.8 g per meal at two-week intervals to achieve target serum phosphorus.
Chronic Kidney Diseases (Pediatric, >=6 years) Starting dose 0.8-1.6 g three times daily with meals based on body surface area (BSA) category; titrate based on BSA category at two-week intervals for 6 weeks then every 4 weeks as needed.
Contraindications
- History of serious hypersensitivity reaction to INPEFA
- Bowel obstruction
- Known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or any excipient
Adverse Reactions
Most common (>=2%) Urinary tract infection, volume depletion, diarrhea, hypoglycemia, dizziness, genital mycotic infection
Serious Diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, hypoglycemia with insulin and insulin secretagogues, necrotizing fasciitis of the perineum, genital mycotic infections
Most common (>5%) Vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, constipation
Postmarketing Hypersensitivity, pruritus, rash, abdominal pain, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, fecal impaction, ileus, intestinal obstruction, intestinal perforation
Pharmacology
Sotagliflozin is a dual inhibitor of SGLT2 and SGLT1; SGLT2 inhibition reduces renal reabsorption of glucose and sodium (lowering cardiac pre- and afterload and downregulating sympathetic activity), while SGLT1 inhibition reduces intestinal absorption of glucose and sodium.
Sevelamer carbonate is a non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium, that binds phosphate in the gastrointestinal tract via ionic and hydrogen bonding, thereby decreasing phosphate absorption and lowering serum phosphorus concentrations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inpefa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (10/12)
Renvela
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (4/12) · Qty limit (9/12)
UnitedHealthcare
Inpefa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Renvela
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Inpefa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Renvela
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/fillfill
Inpefa Savings Card ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Renvela.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InpefaView full Inpefa profile
RenvelaView full Renvela profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.